title: The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac.
authors.affiliation: European Medicines Agency, London, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Arlett
authors.forename: Sinan B
authors.initials: SB
authors.lastname: Sarac
authors.forename: Andrew
authors.initials: A
authors.lastname: Thomson
authors.forename: Claire
authors.initials: C
authors.lastname: Davies
authors.forename: Tania
authors.initials: T
authors.lastname: Teixeira
authors.forename: Kevin V
authors.initials: KV
authors.lastname: Blake
authors.forename: Doris
authors.initials: D
authors.lastname: Stenver
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D003657:Decision Making; D004008:Diclofenac / Q000009:adverse effects*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D005062:European Union; D006801:Humans; D060735:Pharmacovigilance; D012106:Research / Q000458:organization & administration; D018570:Risk Assessment
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004008:Diclofenac